Human Insulin Like Growth Factor-2 Recombinant
Categories: IGF familyIGF familyRecombinant Human Cytokines$70.00 – $1,700.00
Description
Accession
P01344
Source
Optimized DNA sequence encoding Insulin Like Growth Factor-2mature chain was expressed in Escherichia Coli.
Molecular weight
Native human Insulin Like Growth Factor-2 is generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately7 kDa. RecombinantIGF-2 is a monomer protein consisting of68 amino acid residue subunits, and migrates as an approximately7 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Purity
>97%, as determined by SDS-PAGE and HPLC
Biological Activity
The ED(50) was determined by the proliferation ofFDC-P1 cells and was found to be is ≤.0 ng/ml, corresponding to a specific activity of ≥1 x units/mg.
Protein Sequence
MGIPMGKSML VLLTFLAFAS CCIAAYRPSE TLCGGELVDT LQFVCGDRGF YFSRPASRVS RRSRGIVEEC CFRSCDLALL ETYCATPAKS E RDVSTPPTV LPDNFPRYPV GKFFQYDTWK QSTQRLRRGL PALLRARRGH VLAKELEAFR EAKRHRPLIA LPTQDPAHGG APPEMASNRK
Endotoxin
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Presentation
Recombinant IGF-2 was lyophilized from a 0.2 μm filtered PBS solution pH7.5.
Reconstitution
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Storage
The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at2° -8° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage
This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
Interactor
P08833
Interactor
P11717
Interactor
Biological Process
Biological Process
Molecular function
Molecular function
Molecular function
Methods
IGF2 infusion reduces the number of Aβ40 and Aβ42 plaques in the hippocampus.
- IGF2 treatment significantly reduced the number of hippocampal plaques as determined by one-way ANOVA with repeated measures [A, F(1,10) = 6.987, p = 0.027; B, F(1,10) = 6.483, p = 0.029].
BMP and FGF are robust trophic factors for purified astrocytes.
- 5 ng/ml HbEGF (positive control), as well as 100 ng/ml BMP5, 100 ng/ml IGF2 and 10 ng/ml FGF2 each significantly increase astrocyte viability above control .
